About Us
Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies
Pharmazz, Inc.
Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.
Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.
The company is developing three novel first-in-class drug products across multiple critical care indications. Its lead product, Centhaquine, is for Hypovolemic Shock where a new therapeutic is greatly needed. Pharmazz’s second compound, Sovateltide, is for cerebral ischemic stroke, Alzheimer’s disease, and other neurodegenerative diseases. A third compound is being developed for undisclosed indication.
RoadMap ↓
Pharmazz licenses Dr. Reddy's Laboratories rights to market Centhaquine (Lyfaquin®) as a resuscitative agent for hypovolemic shock in India - March
Pharmazz and Sun Pharma entered into an agreement under which Sun Pharma invests up to $15 Million in Pharmazz - August
DCGI approved the manufacture and marketing of Sovateltide Injection for patients with Acute Cerebral Ischemic Strock (ACIS) in India - May
US-FDA approved Phase III Clinical Trial of Centhaquine for hypovolemic shock - September
Pharmazz licenses Sun Pharma rights to market Sovateltide (Tyvalzi™) in India for Cerebral Ischemic Stroke patients - September
US-FDA approved a Phase II clinical trial of centhaquine for Acute Respiratory Distress Syndrome (ARDS) - April
Centhaquine Market Approval (India) - May
Lyfaquin® (centhaquine) launched - November
Sovateltide Phase III for Stroke - July
Sovateltide Phase II for Acute Spinal Cord Injury - October
Centhaquine Phase III - December
Sovateltide Phase II for Stroke - August
Sovateltide Phase II for Alzheimer’s disease - August
Sovateltide Phase I - July
Centhaquine Phase II - December
Licensing agreement with University of Illinois - January
Centhaquine Phase I - September
Licensing agreement with Midwestern The University - January Pharmazz India Private Limited started - March
Incorporated - October